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A. MEHRUNNISA 
INTRODUCTION 
Malaria is essentially a disease of the poor countries and 
included under 'Tropical diseases' by WHO, Geneva. Of the 
estimated 500 million episodes and 2.7 million deaths from malaria 
every year, over 90 percent occur in the African sub-continent 
(WHO, 1996). The disease is endemic in about 91 countries with 
many pockets of transmission in countries like India. Brazii 
Afghanistan, Sri Lanka, Thailand, Indonesia, Vietnam, Combodia 
and China and takes lives of millions of people every year globally 
Malaria was almost eliminated from India in early 1960s through 
extensive use of insecticides and antimalarials and number of cases 
came down to 0.1 million from 75 million. Resurgence of malaria 
occurred in 1970s because of technical and financial problems 
(Sharma, 1984 & Sharma and Mehrotra, 1986). In 1990's malaria re-
emerged because of insecticide resistance in vector and drug 
resistance in the parasite, killing thousands of people 
More than 100 Plasmodium species have been described 
causing malaria in a wide range of vertebrates and exhibiting 
narrowly defined host-specificity (Garnham, 1980). Among 100 
species only four infect man which are Plasmodium vivax 
Plasmodium falciparum, Plasmodium malariae and Plasmodium 
ovale. In India we have Plasmodium vivax and Plasmodium 
falciparum causing benign and malignant tertian malaria. In India 
60-65% of the malaria infections are reported to be due to 
Plasmodium vivax and 30-35% due to Plasmodium falciparum (Adak 
et al. 1998). Of all species of human Plasmodia, Plasmodium 
falciparum is highly pathogenic causing malignant tertian malaria as 
a result of which lot of morbidity and mortality takes place. This 
parasite shows resistance against routine curative drugs such as 
chloroquine, amodiaquine, metakelfin, fansidar and mefloquine in 
endemic areas and posing serious problems in cure of this disease 
An increasing number of malaria epidemics has been 
documented throughout the world. A changing scenario of malaria is 
observed and it is found that malaria had been changing its clinical 
profile. The classic paroxysm is evident in only 40% cases of 
Plasmodium falciparum and 47% Plasmodium vivax. On the other 
hand in rest of the cases continuous or remittent type of fever has 
been observed. Association of jaundice along with hepatomegaly 
has also been observed in Plasmodium falciparum and Plasmodium 
vivax infections. Splenomegaly along with respiratory distress 
oligurea with impaired renal function and convulsion or coma has 
also been observed (Hazra et al. 1998). 
Available informations indicated that Plasmodium falciparum 
has given rise to formidable drug resistant strain in Asia. The 
problem of chloroquine resistance in Plasmodium falciparum is 
widespread and now it is leading towards multiple drug resistance 
against all major antimalarials. Sharma (1999) indicated that in high 
transmission areas in India there are about 30% cases which 
showed some level of drug resistance against standard dosage of 
curative drugs. Follow up studies showed relapses in Plasmodium 
vivax infections. Now reports are coming up regarding tolerance of 
Plasmodium vivax against standard dosage of therapeutic and 
antirelapse drugs (chloroquine and primaquine) and showing 
complications somewhat similar to that of falciparum malaria In 
February 1999 KEM hospital in Mumbai recorded first case of vivax 
malaria showing resistance against routine curative drugs. 
Keeping above facts in view present study was conducted to 
find out proportion of Plasmodium vivax and Plasmodium falciparum 
infections and their relapsing and resistance patterns in Aligarh. 
HISTORICAL REVIEW 
The malaria parasite have been with us since the dawn of 
time. They probably originated in Africa. Fossils of mosquitoes up to 
30 million years old show that the vector for malaria was present 
well before the earliest history. The specific fever caused by malaria 
parasites known as 'Agues' received the Italian name 'Malaria', 
since it was then widely believed that their cause was related to the 
foul air common near marshy areas. The most important event in the 
history of malaria took place towards the end of 19"^ century when 
the workers in the field of bacteriology and pathology were 
discovering the cause of infectious disease, observing the morbid 
change in the organs and tissues. 
In 1880 Laveran first saw and described malaria parasite in 
the blood cell of man. Celli and Marchiafava (1889-90) in Italy 
described Plasmodium falciparum. Romanowsky (1890-91) 
developed a new method of staining malaria parasites in blood fi lm. 
Manson put forward the theory of malaria transmission from man to 
man by mosquito in 1894. Ross (1897) discovered pigmented cyst 
on the stomach wall of an anopheles mosquito (probably An 
Stephensi) in India. In (1898) Grassi et al. described the cycle of 
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human malaria parasite in anophelesTfTQSquitoes. Patrick manson in 
1900 proved the theory of mosquito transmission. In 1922 Stephen 
identified and described Plasmodium ovale. James in 1931 reviewed 
Grassi's theory and suggested that the sporozoites soon after 
entering the body, Invades reticulo-endothelial cells or cells lining 
the capillaries of blood vessels. Short et al. (1948-49) described 
pre-erythrocytic form of Plasmodium vivax and Plasmodium 
falciparum in human liver. In 1952 Jeffery et al. demonstrated a 3-
day old pre-erythrocytic schizont of Plasmodium falciparum in 
human liver. Garnham et al. 1954 discovered schizogony of 
Plasmodium ovale. 
Epidemiological studies conducted in Gambella, southern 
Ethiopia, Thailand and India (Nigatu et al. 1992, Thimasank et al. 
1995 and Sharma, 1996) indicate that the most probable 
contributing factors for malaria transmission pattern were the 
rehabilitation and resettlement programmes and agricultural 
activities undertaken In these countries during past ten years that 
may have brought changes in socio-economic situation and 
environmental factors. Most of the work in the field of malaria are 
being done on Plasmodium falciparum causing malignant infection 
and Plasmodium vivax which cause benign infection. Lot of mortality 
takes place because of Plasmodium falciparum infection each year 
and therefore much attention is paid to this parasite. It Is found that 
Plasmodium falciparum infection is emerging in endemic areas 
(Mandal et al. 1998). A competition is going on between Plasmodium 
vivax and Plasmodium falciparum to gain upperhand as a result of 
which a changed scenario of malaria transmission is observed 
Unusual acute and chronic complications of malaria were recorded 
in Delhi by Mehta et al. 1996 with manifestations of tachypnoea and 
pulmonary oedema and shock due to multiple organ dysfunction 
syndrome. Other features were meningitis, renal fai lure, hepato-
renal syndrome and neck stiffness etc. 
Most of the reports and cross checking in different parts of the 
world indicate that Plasmodium falciparum has developed resistance 
against standard dosage of curative drugs. As far drug resistance Is 
concerned, Plasmodium falciparum showed resistance against 
chloroquine, amodiaquine, metakelfin, fansidar and mefloquine 
Resistance in Plasmodium falciparum to amodiaquine and quinine 
was reported in Madang province of Papua New Guinea by Alyaman 
et al. (1996). Multiple drug resistance was observed in falciparum 
malaria by McGready e^ al. between 1991-96 in pregnant women 
living in western border of Thailand. They were treated with either 
mefloquine, quinine or both. Out of those treated with mefloquine 
6% failed to clear parasitaemia by day 7 and 28% by day 24 
Therapeutic effects of chloroquine in combination with quinine in 
uncomplicated falciparum malaria were studied in 50 Thaimen by 
Vanjanantas et al. 1996. They treated all the patients for 7 days with 
quinine (10 mg base/ kg, every 8 hourly). A group of patients 
selected randomly was given oral tetracycline (4 mg/kg, 4 times 
daily) for the same period while patients in other group were given 
chloroquine for the first three days. Overall clearance time in the 
chloroquine or tetracycline group were not significantly different. 
Recrudescence (R-1 level) were higher in chloroquine group than in 
tetracycline. Survey conducted during last decade showed that 
Plasmodium falciparum has become resistant to chloroquine in 
Pakistan and Afghan refugees (Shah et al. 1997). A repeated in vivo 
survey indicated that prescription of chloroquine can lead to 15% 
increase in the frequency of resistance in a single year. The 
therapeutic efficacy of chloroquine was assessed by Mharakarwa e^ 
al. 1997 who reported resistance in 52% patients following 
chloroquine treatment. In 64 cases of uncomplicated falciparum 
malaria in Zimbabwe they noticed a modest reduction in a sexual 
parasite density and clinical symptom. However, there was an 
appreciable therapeutic failure of chloroquine which has declining 
clinical value as the first line of presumptive treatment for 
uncomplicated malaria. It is therefore recommended in Zimbabwe 
that the second line antimalarial sulphadoxine - pyrimethamine 
should be disrtibuted to health centre level for patients suffering 
from malaria. Bojang et al. (1998) noticed failure of fansidar and 
chloroquine in Gambian children in India. Ghosh et al. (1992) 
reported that 58.3% Plasmodium falciparum cases did not respond 
to single dose of chloroquine (10 mg base/kg) in vivo test. With 
standard dose (25 mg base/kg) 31.2% cases showed resistance i.e 
Rl (5.6%), Rll (9.4%) and Ril l (6.2%) levels. Garg e^ al. (1996) 
treated 17 uncomplicated falciparum malaria patients resistant to 
chloroquine with 3 tablets of sulphadoxine - pyrimethamine. Out of 
17, 14 patients responded and were sensitive while 3 patients 
showed Rll grade resistance to sulphadoxine pyrimethamine. These 
3 patients then responded to a 7 day course of quinine + 
doxycycline. Hazra et al. (1998) studied 60 cases of Plasmodium 
falciparum and 165 cases of Plasmodium vivax clinically. It was 
observed that malaria had been changing its clinical profile. The 
classic paroxysm was evident only in 40% cases of Plasmodium 
falciparum and Al.21% of Plasmodium vivax malaria. On the other 
hand remittent type of fever had been observed in 40% and 27.2% 
cases of Plasmodium falciparum and Plasmodium vivax, 
respectively. Absence of classic paroxysm of fever, in association 
with splenomegaly was reported in 80% and 63.63% of these 
infections in conjunction with nausea and / or vomiting leading to 
clinical minnicry with infective hepatitis. Splenomegaly which has 
been described as cardial feature of malaria was observed in 40% 
cases with Plasmodium falciparum and 18.18% cases of Plasmodium 
vivax. Coexistence of intense fever was observed in 3.33% of 
falciparum and 2.6% of vivax malaria. 
Plasmodium vivax infection caused by strains with low 
sensitivity to primaquine are widespread in western pacific and 
south-east Asia and have recently been reported from centra! 
America as well (Signorini et al. 1996). A case of primaquine failure 
in Plasmodium vivax infection was recorded in Guatemala. A 28 year 
old Italian women had vivax attack 2 months after returning from 
Guatemala who was treated there with chloroquine course (1500 mg 
over 3 days) alongwith primaquine (15 mg/ day) for 14 days. Two 
months later she had a relapse that was again treated with 
chloroquine and primaquine at the same dosage. After 3 months a 
second relapse occurred. This time primaquine (30 mg/ day for 14 
days) was administered. The patient remained well during a follow 
up period of 6 months. Dosage of primaquine as high as 6 mg/kg 
body weight is recommended in the treatment of vivax malaria in 
central America. 
Vivax malaria is most frequent imported malaria in Japan 
comprising about 60% of the total cases. Patients were usually 
treated after acute phase therapy of chloroquine with standard 
course of primaquine (15 mg base daily for 14 days) as curative 
therapy. Recently however cases of relapse of vivax malaria after 
this standard primaquine therapy are reported from various 
countries such as Japan, New Guinea, Thailand and Indonesia. In 
contrast the relapse rates of cases acquired in India are low. Most 
of the relapsed cases are successfully treated with either of these 
regimen (i) 20 mg/day for 7 days (ii) two courses of the standard 
primaquine therapy given one month apart (iii) 15 mg/ day for 21 
days without noticeable side effects. It is imperative to establish the 
most appropriate regimen with primaquine for curative treatment of 
vivax malaria contracted in the areas mentioned above. Smoak et a/ 
(1997) studied relapse patterns in US army troops in Somalia 
Following initial attack of malaria 60 of 75 cases received a 
standard course of primaquine (15 mg base daily for 14 days). 26 of 
60 soldiers subsequently relapsed with a failure rate of 43%. 8 
soldiers had second relapse following primaquine therapy after both 
primary attack and first relapse. 3 of these soldiers had received a 
higher dose of primaquine (30 mg base daily for 14 days) after their 
second attack. The apparent ineffectiveness of primaquine therapy 
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in preventing relapse suggest the presence of primaquine resistant 
Plasmodium vivax strain in Somalia. 
Studies conducted on Plasmodium vivax infections indicate 
that the parasite show tolerance against both therapeutic and 
antirelapse drugs. A study on relapse / reinfection pattern of 
Plasmodium vivax was conducted in district Shahjahanpur by Prasad 
et al. (1991) who reported maximum number of relapse/ reinfection 
in a 47 year old male patient, who suffered 8 times. They have 
indicated that relapse rate was high in males (70.2%) as compared 
to females (29.8%). A study on relapse pattern of Plasmodium vivax 
was conducted by Sharma et al. (1990) in Kheda district of Gujrat 
where relapsing tendency in Plasmodium vivax was observed within 
8 months of primary attack. Relapse rate was 2.6% within one year 
in patients treated with 5 days course of primaquine. Immune 
response of Plasmodium vivax in a cross-section of the population 
in Delhi area was studied by Ray et al. (1994). They observed 
antibodies against crude blood stage antigen in majority of the 
individuals who were acutely infected with Plasmodium vivax 
Studies on Plasmodium vivax relapse pattern was conducted in 
Kheda hospital by Srivastava et al. (1996). They treated one group 
of patients with 600 mg chloroquine and other with 600 mg 
chloroquine and 50 mg pyrimethamine which yielded 28.3% and 
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27.3% relapse rates, respectively. They have also noticed more 
short-term relapses (within 2-3 months) and a few long-term 
relapse. A five-year epidemiological study of patients attending a 
malaria clinic in Delhi was conducted by Adak et al. (1998) to find 
out the relapse rate in Plasmodium vivax infections. They have also 
observed with seasonal correlation between the primary infection 
and subsequent relapses, the duration of the incubation period, and 
the pattern of relapse. They recorded relapse rate between 23% to 
44% depending on the short and long durations of the follow up. 
It has also been reported recently that Plasmodium vivax has 
developed resistance to chloroquine. Baird e^ al. (1997) noticed 
chloroquine resistant strain of Plasmodium vivax in Indonesia, 21 
patients infected with Plasmodium vivax were given chloroquine 3 
of them had recurrent asexual Plasmodium vivax parasitaemia 
between day 14 to 18 despite effective levels of chloroquine at the 
time of recurrence. Resistance to standard chloroquine therapy by 
Plasmodium vivax was noticed in 14% cases. Marlerthan et al. 
(1995) noticed resistance to standard chloroquine therapy by 
Plasmodium vivax infections, in Myanmar. 50 patients with 
Plasmodium vivax infection were treated with standard regimen of 
chloroquine phosphate (1500 mg over 3 days) followed by 45 mg 
primaquine immediately and then weekly for 8 weeks. 43 patients 
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showed recrudescence between day 3 and 14 with Rl, Rll and Ril l 
pattern in 1, 3 and 3 patients, respectively. All the chloroquine 
resistant cases were again treated with 1500 mg chloroquine and no 
further recrudescence or relapse were detected. In February 1999 in 
India KEM Hospital in Mumbai recorded first case of vivax malaria 
showing resistance against routine curative drugs. 
13 
MATERIALS AND METHODS 
Present study is based on the malaria cases enrolled in 
Medical college and a few other hospitals and clinics of Aligarh 
during years 1998 and 1999. Blood smears were prepared from 
patients who attended hospitals and clinics, complained for fever 
and headache and were suspected for malaria. Thick and thin blood 
smears of patients were prepared by fingerprick, stained with 
Jaswant Singh and Bhattacharya and Giemsa stains and 
microscopically examined under an oil immersion lens to see the 
positively for malaria infection. 
Preparation and fixation of blood smear 
Good quality clean glass slides of about 1.2 mm thickness 
were used for making smears. Greasy sides were first cleaned by 
boiling with detergents, subsequently scrubbed and washed 
thoroughly in running water so as to remove all traces of detergents 
and grease. For making blood smear the tip of middle or ring finger 
of the left hand was cleaned with spirit swab and allowed to dry 
completely before pricking. Two drops of blood were collected one 
for thick smear and the other for thin. The thick smear was made in 
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such a way that the edge of smear remain approximately 1.0 cm 
away from the edge of the slide. The distance between the edge of 
thick and thin smear was about 0.75 cm. Only thin smear were fixed 
with methyl alcohol. After drying, slides were stained with Giemsa 
and JSB stains as described by Singh (1956). 
Preparation of staining solutions 
(i) Preparation of JSB-1 solution: 
For preparation of JSB-1 solution 0.5 mg of methylene blue 
was dissolved thoroughly in 500 ml distilled water in flask. 3 ml of 
one percent sulphuric acid was added drop by drop to the solution 
and then mixed with 0.5 gm of potassium dichromate. Addition of 
potassium dichromate led to the formation of some precipitate and 
at this step 3.5 gm of disodium hydrogen phosphate dihydrate was 
added. The mixture was boiled for half an hour. The stain was 
allowed to cool at room temperature and was ready for use as JSB-1 
solution. This solution when used after maturation of 2-3 weeks 
gave better results. 
(i i) Preparation of JSB-II solution 
It was prepared by dissolving 1 gm of water-soluble eosine In 
500 ml of distilled water. A freshly prepared eosine solution, 
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although can be used immediately, may not yield as satisfactory 
result as the one which has turned deep red after some storage. 
(Mi) Preparation of buffer water 
This was prepared by dissolving disodium hydrogen phosphate 
dihydrate (0.22 gm) and potassium acid phosphate (0.74 gm) in one 
litre distil led water. To maintain initial pH buffered water was kept in 
glass bottles. 
Staining 
Slide staining was done with JSB In following steps: 
(a) 2-3 dips in JSB-II 
(b) Washing ten times with buffer water 
(c) A dip of 45 seconds in JSB-1 
(d) Washing ten times with buffer water 
(e) Drying thoroughly before examination 
A good number of slides were also stained with Giemsa. For 
staining with Giemsa, smears were first fixed in methanol and dried 
in air by waving hand. Dried slides were transferred in Giemsa stain 
for 3-5 minutes then passed on to the same stain diluted with 
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distilled water (1:1) and allowed it to stain for 15-20 mts. Finally 
slides were washed thoroughly under tap water and dried. 
Examination of slides 
Slides were examined under the microscope with 10 x and 40 
X objectives to see the positivity for malaria parasite. Positive slides 
were then thoroughly examined under an oil immersion lens (100 x) 
to ascertain the type of infection (i.e. Plasmodium vivax. 
Plasmodium falciparum or mixed type). 
From malaria positive cases monthly Plasmodium vivax and 
Plasmodium falciparum infections and their percentage in adults and 
children was worked out. Month-wise slide positivity rates (SPR) and 
slide falciparum rates (SFR) were also worked out for the years 
1998 and 1999. Resistant and relapse cases were also recorded in 
Plasmodium falciparum and Plasmodium vivax infections, 
respectively. 
Drug resistance in Plasmodium falciparum infections 
For drug resistance, patients who were positive for 
Plasmodium falciparum infection were given 1500 mg chloroquine 
base in divided doses (i.e. 600 mg on day 0, 300 mg after 8 hours 
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followed by 300 mg daily for 2 days). The dose of child was adjusted 
accordingly. Blood films of those patients who reported back with 
fever within 4 weeks of treatment were examined for the 
Plasmodium falciparum infection. If found positive such cases were 
recorded as chloroquine resistant cases. Level of resistance (i.e. Rl, 
Rl l , Ril l) was ascertained on the basis of late and early 
recrudescence. 
Relapse in Plasmodium vivax infections 
For the study of relapse in Plasmodium vivax, one group of 
patients was treated by giving 1500 mg chloroquine base in divided 
doses (i.e. 600 mg on day 0, 300 mg after 8 hours followed by 300 
mg daily for 2 days). The dose of child was adjusted accordingly. 
While patients in other group were administered 1500 mg 
chloroquine in the similar manner followed by 15 mg primaquine 
daily for 5 days and then followed up carefully. To determine the 
pattern of relapse in Plasmodium vivax each patient was identified 
individually by name, address and subsequent treatment. On 
reporting back blood smears were prepared from the patient and 
examined microscopically for the presence of malaria parasite and 
entered against his/ her name. 
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The following criteria were used in classifying the patients into 
primary cases and non-relapse and relapse categories in the 
present study. Patient reporting for the first time (having no history 
of malaria) with acute illness and showing symptoms such as high 
fever, severe headache, loss of appetite, occasional vomiting and 
microscopic evidence of Plasmodium vivax infection were 
considered as primary cases. Some patients in this group who had 
no clinical symptoms of malaria or parasitological evidence of 
Plasmodium vivax infection following their primary infection during 
the entire study period were considered as non-relapse cases 
Those patients who reported back to the clinic within one month to 
one year with renewed clinical symptom (mild) along with a periodic 
alternate day fever (not observed in the primary cases) and found to 
be microscopically positive for Plasmodium vivax infection were 
considered as relapse cases. After medication if patients again 
suffered from malaria within 3 months with more regular paroxysm 
he/she was treated as a case of short-term relapse. But if it 
happened beyond 3 months then the case was considered as a long-
term relapse. Cases of Plasmodium vivax who did not respond to 
1500 mg of chloroquine and 75 mg primaquine were recorded as 
chloroquine resistant cases. 
19 
RESULTS 
Table I and II show month and year data on Plasmodium vivax 
and Plasmodium falciparum cases in the present study. These 
tables also provide information on seasonality. Plasmodium vivax 
infection was predominant and was recorded in all months of the 
year with almsost similar seasonal pattern during the two-year study 
period. Plasmodium vivax show a gradual increasing trend from May 
onwards reaching a peak in September soon after the rainy season 
and then decline sharply to very low level in December. Plasmodium 
falciparum infections started appearing in August and showed peak 
in September and October and decreased sharply with the onset of 
winter (Graph I and II). 
During 1998 out of 1256 slides examined, 391 were found 
positive for malaria of which 272 belonged to Plasmodium vivax and 
119 to Plasmodium falciparum (Table-I). In 1999 a total of 1526 
slides were examined, out of which 496 were positive for malaria 
Slides showing positivity for Plasmodium vivax and Plasmodium 
falciparum were 307 and 187, respectively (Table-l l). During years 
1998 and 1999 overall percentage of Plasmodium vivax and 
Plasmodium falciparum infections were 49.56 and 62.2 and 30.43 
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Signet ring stage of P. vivax 
Schizont stage of P. vivax 
and 37.8, respectively. During these years infection rates in adults 
and children ranged between 62.2 to 64.7% and 35.2 to 37.7% 
respectively (Graph III and IV). 
It was observed that malaria transmission was least from 
January to April. During the months of May, June and July 
transmission was low with slight fluctuating figures for the years 
1998 and 1999 which was in accordance with the commencement of 
pre-monsoon shower that contributed slightly increased or 
decreased transmission rate in proceeding months. Increased rate 
of transmission was recorded July onwards, reaching a peak soon 
after rains in September and October followed by a sharp decline to 
a low level in November and December. During peak transmission 
season mean temperature and relative humidity ranged somewhere 
around 26 to 28°C and 77 to 88%, while in seasons showing low 
transmission rate, temperature was either too low around 12 to 15°C 
or too high around 26 to 34°C which was probably the main factor 
for low malaria transmission (Graph V and VI). 
Plasmodium vivax and Plasmodium falciparum showed almost 
similar transmission pattern during the years 1998 and 1999 having 
mean SPR 31.18 and 30.78, respectively. A considerable degree of 
fluctuation was observed during peak transmission season (i e 
September and October) when SPR was comparatively high and 
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Gametocyte of P. vivax 
ranged between 36.3 and 44.6% (Table-I and II). Plasmodium 
falciparum infection was also proportionately high showing slide 
falciparum rate between 12.9 and 16% during these months for both 
the years followed by a low rate (i.e. 5.7 to 8.08%) during winters 
and lowest in summer which ranged from 2.3 to 5 .1%. 
Table III shows yearly analysis of P. vivax, non-relapse versus 
relapse patients and the relapse rate percentage with different 
follow up durations. In 1998, the total number of Plasmodium vivax 
patient was 150. Of which 126 did not have any further relapse, 
whereas 24 had relapses in two year follow up study, giving a 
relapse rate of 16%. Similarly for year1999 the relapse rate 
calculated was 11.3%. Short-term relapses were more then the long-
term relapses in the ratio of about 3:1 for both the years. In 1998 
and 1999 short and long-term relapses were recorded as 12 and 4% 
and 7.8% and 3.4%, respectively. Above percentage of relapse was 
recorded in patients who were given 1500 mg chloroquine in divided 
doses in adults (600 mg on day 0, 300 mg after 8 hours followed by 
300 mg daily for two days). 65 patients who were administered with 
1500 mg chloroquine and 75 mg primaquine in divided doses also 
showed relapses in 3.07% cases. During entire study period three 
Plasmodium vivax cases showed resistance against chloroquine as 
the parasite showed recrudescence on 9 ' \ 11*^ and 14^ "^ day after 
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Signet ring stage of P. falciparum 
Gametocyte of P. falciparum 
the administration of standard dose of 1500 mg chloroqulne and 75 
mg of primaquine. 
Table IV shows the frequency distributions of 80 and 140 
patients, showing resistance against chloroquine in 7.5 and 10% 
cases after getting 1500 mg chloroquine base in divided doses (600 
mg on day 0, 300 mg after 8 hours followed by 300 mg daily for two 
days). Plasmodium falciparum primary attach recorded in 
individuals who did not have any previous malaria history during 
non-transmission months, particularly from December to June in 
order to rule out possibility of recrudescence because of incomplete 
medication. Of 80 patients studied during year 1998 seventy four 
were susceptible whereas 6 patients showed resistance against 
chloroquine. The level of resistance was Rl and Rll type in 5 and 
2.5% cases as they relapsed around 10"^ and 5'*^  day after 
medication. Similarly during year 1999 out of 140 cases studied, 126 
were susceptible while 14 showed resistance, out of which 6.4% 
were of Rl type and 3.5% were of Rll type. 
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TABLE-I 
Prevalence of malaria showing parasite distribution, SPR and SFR during 
year1998 
Years 
Jan 
Feb 
Mar 
Apr 
May 
Jun 
Jul 
Aug 
Sep 
Oct 
Nov 
Dec 
BSE 
52 
57 
39 
55 
43 
72 
98 
120 
280 
220 
140 
80 
Total cases 
15 
20 
12 
12 
13 
25 
15 
24 
125 
80 
30 
20 
P. vivax 
11 
16 
10 
10 
10 
20 
12 
16 
80 
50 
22 
15 
P. falciparum 
4 
4 
2 
2 
3 
5 
3 
8 
45 
30 
8 
5 
SPR 
28.8 
35 
30.7 
21.8 
30.2 
34.7 
15.3 
20 
44.6 
36.3 
21.4 
25 
SFR 
7,6 
i 
7,0 \ 
^ 5 . 1 1 
3.6 
6.9 
6.9 
3.06 
6.6 
16 
13.6 
5.7 
6.2 
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TABLE-II 
Prevalence of malaria showing parasite distribution, SPR and SFR during 
year1999 
IMonths 
Jan 
Feb 
Mar 
Apr 
May 
Jun 
Jul 
Aug 
Sep 
Oct 
Nov 
Dec 
BSE 
43 
23 
25 
42 
33 
48 
75 
156 
482 
350 
150 
99 
Total cases 
13 
10 
8 
6 
15 
11 
20 
32 
191 
133 
39 
19 
P. vivax 
10 
8 
7 
5 
12 
9 
16 
26 
129 
85 
22 
11 
P. falciparum 
3 
2 
1 
1 
3 
2 
4 
6 
62 
48 
17 
8 
SPR 
30.2 
43.5 
32 
14.2 
45.6 
22.91 
26.6 
20.5 
39.6 
38 
9.8 
19.1 
SFR 
6.9 
8.7 
4 
2,3 
9.09 
4.16 
5.33 
3.8 
12.9 
13,71 
4.2 
8.08 
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TABLE-III 
Relapse cases in Plasmodium vivax infection 
Year 
1998 
1999 
1999 
Total no. 
of P. vivax 
patients 
obsen e^d 
150 
115 
65* 
Non-
relapsing 
patients 
126 
102 
63 
Relapsing 
patients 
24 
13 
2 
Short-
term 
relapse 
18 
9 
2 
Long-
term 
relapse 
6 
4 
0 
Relapse 
rate 
16 
11.3 
3.07 
Follow up 
years 
2 
1 
0.5 
Patients given 75 mg primaquine base following chloroquine treatment 
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TABLE-IV 
Chloroquine resistant cases in Plasmodium falciparum infection 
Months 
1998 
1999 
Total no. of P. 
falciparum 
patients observed 
80 
140 
Non-
Resistant 
patients 
74 
126 
Resistant patients 
"o 
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14 
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DISCUSSION 
Malaria still continues to be the most important vector-borne 
disease causing extensive morbidity and mortality in the tropics 
Malaria parasites belonging to genus Plasmodium are characterised 
by heterogeneous life cycle involving a sexual and sporogonic mode 
of reproduction in the invertebrate host and an asexual reproductive 
mode involving schizogonic cycles in the vertebrate host. 
In the present investigations, patients attending OPD of 
Jawaharlal Nehru Medical College and a few other clinics of Aligarh 
showing symptoms such as high fever, severe headache, loss of 
appetite, occasional vomiting and microscopic evidence of 
Plasmodium vivax and Plasmodium falciparum were considered 
Resistant and relapsing cases were observed in Plasmodium 
falciparum and Plasmodium vivax infections, respectively. 
In the present study peak transmission of malaria during the 
months of September and October which was recorded during year 
1998 and 1999 was probably because of the availability of plenty of 
breading sites for the vector species after rains in proceeding 
months. Moderate temperature (i.e. 26 to 28''C) and optimum 
humidity (i.e. 77 to 88%) during these months which were ideal for 
mosquito breeding might have influenced increase in vector 
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population which must have contributed maximum transmission as 
earlier observed by Adak et al. 1998 in Delhi. Increased 
transmission of malaria was also recorded in Assam in areas having 
streams where vector species An. minimus was abundant 
(Wajihullah et al. 1992 and Jana-kara et al. 1995). Whereas least 
transmission which was recorded from December to June was 
because of adverse environmental factors which caused reduction in 
number of vector species. During these months either extreme dry 
cold or dry heat conditions prevail which affect vectors adversely 
either by making water bodies unsuitable or very slow for breeding 
or by making them scarce as a result of high temperature which 
even kills the vector. 
Percentage for Plasmodium vivax during years 1998 and 1999 
was 69.56 and 62.2 while for Plasmodium falciparum it was 30.4 and 
37.8 indicates a slight decrease in Plasmodium vivax and an 
increase in Plasmodium falciparum infection, if 3:1 ratio (i.e. 75% 
and 25%) is treated as usual one in plains for Plasmodium vivax and 
Plasmodium falciparum infections. Development of resistance 
against routine curative drug (i.e. chloroquine) might have been one 
of the reasons for this increase in Plasmodium falciparum infection. 
As for higher percentage of infection in adults as compared to 
children is concerned, it might be because of the reason that adults 
';r 
are much more exposed to mosquito bite as compared to children 
who are protected by their parents to some extent. Slide falciparum 
rate (SFR) was considerably high during peak transmission period 
as well as in colder months even when transmission rate is low. It is 
difficult to draw exact conclusion but it seems that development of 
Plasmodium falciparum is supported by the vector species more 
readily as compared to Plasmodium vivax, may be it is a particular 
strain of the same vector species which emerges in good number in 
winters and contributed for raised falciparum transmission. Another 
probable explanation may be this, that complicated cases generally 
referred to medical college and a few of them happens to be of 
falciparum malaria, might have contributed to raised number of 
cases. And since we collected maximum cases from medical college, 
SFR obtained in the present study is a bit high. In contrast 
Plasmodium vivax cases are generally treated outside easily cured 
and therefore are not on record, hence its transmission rate, which 
is observed is proportionately low. 
In present study 7.5 and 10% patients suffering from 
falciparum malaria showed resistance by showing recrudescence 
around first and second week following chloroquine treatment during 
1998 and 1999. Sharma (1999) reported 30% resistant cases in high 
transmission zone in India. Many other reports are available in India 
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and abroad which show increasing trend of drug resistance. Ghosh 
et al. (1992) observed 25% chloroquine resistant cases in Orissa 
Shah et al. (1997) reported chloroquine resistant cases in Pakistan 
and Afghanistan. Mharakurwas et al. (1997) reported resistance in 
as much as 52% patients following chloroquine treatment. Bojang et 
al. (1998) reported failure of chloroquine in Gambian children. In 
present study less percentage of resistant cases were recorded 
which might be because of the reason that study was conducted in 
low transmission region were Plasmodium falciparum infection is 
proportionately less. 
A very remarkable observation was made during the present 
study that 3 patients having Plasmodium vivax infection showed 
resistance against chloroquine. Similar observation regarding 
resistance of Plasmodium vivax against chloroquine was made by 
Baird et al. (1997). In another study Marler Than et al. (1995) 
recorded recrudescence between 3 and 14 days following 
chloroquine and primaquine treatment which is in corroboration with 
the present finding where chloroquine and primaquine did not 
respond in few cases. 
Relapse rates In Plasmodium vivax during year 1998 and 1999 
following administration of 1500 mg chloroquine base were 16% and 
11.3%, respectively. Short-term relapses were more (12 and 7.82%) 
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as compared to long term relapses, which were 4 and 3.4%. But 
relapse rate was quite low (i.e. 3.07%) and was of short-term type, 
when 75 mg primaquine base was also administered following 
chloroquine treatment. This indicates that both chloroquine and 
primaquine were not fully effective even when they were 
administered in a total curative dose to the patients suffering from 
v/Vax malaria. Similar observations were made by Srivastava et al. 
(1996) who recorded more short-term relapses and a few long-term 
relapse after administration of 600 mg chloroquine, is in accordance 
with our finding where more short-term relapses were recorded, 
Adak et al. (1998) recorded 23-44% relapsing cases within a period 
of 5 years study after giving 900 mg chloroquine in 2 doses (600 mg 
+ 300 mg). Smoak (1997) observed relapses in 43% Somalian 
soldiers who received standard dose of primaquine. In these studies 
relapse rates were high as compared to our findings. It may be 
because of the reason that anti-relapse drug, primaquine was not 
administered by Adak et al. while in case of Smoak's study, may be 
strain of Plasmodium vivax was more tolerant to anti-relapse drug, 
primaquine and did not respond to it in a fairly good number of 
cases. 
Regarding interpretation of the results, one may disagree with 
the differentiation of primary attack verses relapse or reinfection. 
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particularly during peak transmission season. However, in the 
absence of any clinical or parasitologic marker, the following 
observations are considered as relevant. In the present study, 
malaria cases detected between December and June (the supposed 
non-transmission season) could be grouped in three categories: 
(1) Infections acquired in the previous transmission season 
i.e., between July and November but remained undetected and thus 
untreated. (2) Infections acquired during the previous transmission 
season that were detected, treated and subsequently reappeared 
(relapse); or (3) Infections acquired during the previous 
transmission season that became clinically and parasitologically 
positive after a prolonged period (delayed primary attack). 
Although the reinfection particularly during the main 
transmission season could not be ruled out, real transmission from 
December to June is probably occasional and at a very low level, if 
it occurs. Therefore the majority of cases detected during the 
supposed non-transmission period with a definite history of malaria 
were considered to be relapse rather than reinfections, whereas 
those detected with a history of malaria were considered delayed 
primary attacks. However, some uncertainty still exists regarding the 
possibility of reinfiection during the supposed non transmission 
season, which probably will persist until some diagnostic tool is 
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developed that can distinguish the primary attack and subsequent 
relapse from reinfection. 
It is quite evident from the duration of follow up study (1-2 
years) that the average resistance rate for the year 1998 was 7.5% 
and for the year 1999 (10%). The relapse rate for the year 1998 and 
1999 were 16% and 11.3% respectively. Therefore the present drug 
policy of the National Malaria Eradication Programme for the 
administration of primaquine (15 mg of base, once a day for five 
consecutive days) for radical cure of Plasmodium vivax infection 
warrants its reconsideration. 
The mechanism of long survival of Plasmodium vivax during 
non-transmission months through primary long incubation and 
relapses actually ensures transmission in the next season through 
the existence of a reservoir of Plasmodium vivax. It is assumed that 
the primary long and late relapse mechanism of Plasmodium vivax 
might have evolved to survive into the next transmission season and 
be dormant to avoid the host immune response. 
In view of this information, it is suggested that the frequency 
distribution/ratios of different parasite forms responsible for different 
relapse patterns should be determined in different Plasmodium vivax 
ecosystems with reference to space and time, which are probably 
not constant and likely to be time dependent. In addition, the degree 
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to which these parasite sub populations interact with each other will 
no doubt have an impact on the maintenance of genetic diversity 
and regulation of the parasite population as a whole. However, in 
the absence of parasitologic and clinical markers, it may be difficult 
to characterise these forms, perhaps amplification of specific DNA 
sequences by the polymerase chain reaction using specific 
oligonucleotide probes from different parasite isolates of relapsing 
and non-relapsing patients could be used to analyse the genetic 
diversity of the Plasmodium vivax population and correlate this with 
epidemiological findings. Therefore there is a strong need for 
integrated laboratory and field studies as well as the use of 
mathematical models to interpret the complex transmission 
dynamics of Plasmodium vivax and Plasmodium falciparum so that 
appropriate malaria control strategies, including chemotherapeutic 
measures, can be devised. 
In view of the above findings it become evident that in Aligarh 
both resistant and relapse cases are coming up in Plasmodium 
falciparum and Plasmodium vivax infections and it is need of the 
time that at least in cases showing resistance, either increased 
doses of chloroquine must be administered or a revised drug policy 
should be introduced by Malaria Control Programme so that 
alternative drugs should be given for the treatment of malaria 
patients especially those suffering from Plasmodium falciparum 
infection. 
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SUMMARY 
Two years study of patients attending Jawaharlal Nehru 
Medical College and a few other clinics of Aligarh was conducted to 
find out the percentage of Plasmodium vivax and Plasmodium 
falciparum infections. Seasonal correlation of these infections was 
also studied. Relapse and resistance rates were determined in 
Plasmodium vivax and Plasmodium falciparum infections 
Plasmodium vivax and Plasmodium falciparum infections during 
1998 and 1999 were 69.59% and 62.2% and 30.43 and 37.8%, 
respectively. Peak transmission of malaria with a slide positivity rate 
of 38 to 44.6% and slide falciparum rate of 12.9 to 16% was 
recorded during September and October, which happened to be the 
peak transmission months. During these months mean temperature 
ranged around 26 to 28°C while relative humidity was 77 to 88%. 
Lowest transmission was recorded during March and April when 
slide falciparum rate was minimum (2.3 to 5.1%). Relapse rates 
recorded during year 1998 and 1999 were 11.3 and 16% in patients 
received 1500 mg chloroquine. About 7.5% of relapsing cases were 
of short-term type. Patients who received 1500 mg chloroquine and 
75 mg primaquine also relapsed but frequency was less (3.07%). 
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Three chloroquine resistant cases of Plasmodium vivax were also 
recorded in the present study. 75 and 10% patients suffering from 
falciparum malaria during year 1998 and 1999 showed resistance 
against chloroquine. Level of resistance in these cases was of Rl 
and Rl! types. 
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